|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 11 (June 1), 1999:
pp. 3922-3930
Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity
That Is Enhanced by Cytokine Stimulation of Effector Cells
Shuji Ozaki,
Masaaki Kosaka,
Yuji Wakahara,
Yasuko Ozaki,
Masayuki Tsuchiya,
Yasuo Koishihara,
Tetsuya Goto, and
Toshio Matsumoto
From the First Department of Internal Medicine, School of Medicine,
University of Tokushima, Tokushima, and Fuji-Gotemba Research
Laboratory, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan.
To develop a new immunotherapy for multiple myeloma, we have
generated a monoclonal antibody (MoAb) that detects a human plasma cell-specific antigen, HM1.24. Our previous study has shown that mouse
anti-HM1.24 MoAb inhibits the proliferation of human myeloma cells
implanted into severe combined immunodeficiency mice. In this report,
we evaluated the antitumor activity of the humanized anti-HM1.24 MoAb
(IgG1 ), which was constructed by grafting the complementarity-determining regions. In contrast to the parent mouse
MoAb, humanized anti-HM1.24 MoAb mediated antibody-dependent cellular
cytotoxicity (ADCC) against both myeloma cell lines and myeloma cells
from patients in the presence of human peripheral blood mononuclear
cells (PBMCs). The PBMCs from untreated myeloma patients exhibited ADCC
activity as efficiently as those of healthy donors. Although decreased
ADCC activity of PBMCs was observed in patients who responded poorly to
conventional chemotherapy, it could be significantly augmented by the
stimulation with interleukin-2 (IL-2), IL-12, or IL-15. There was a
strong correlation between the percentage of CD16+ cells
and ADCC activity in the PBMCs of myeloma patients. Moreover, peripheral blood stem cell collections from myeloma patients contained higher numbers of CD16+ cells than PBMCs and exhibited
ADCC activity that was enhanced by IL-2. These results indicate that
humanized anti-HM1.24 MoAb has potential as a new therapeutic strategy
in multiple myeloma and that treatment of effector cells with
immunomodulating cytokines can restore the effect of humanized
anti-HM1.24 MoAb in patients with diminished ADCC activity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-T. Tai, M. Dillon, W. Song, M. Leiba, X.-F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Blood,
August 15, 2008;
112(4):
1329 - 1337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sekimoto, S. Ozaki, T. Ohshima, H. Shibata, T. Hashimoto, M. Abe, N. Kimura, K. Hattori, S. Kawai, Y. Kinoshita, et al.
A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment
Cancer Res.,
February 1, 2007;
67(3):
1184 - 1192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al.
Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets.
Endocr. Relat. Cancer,
June 1, 2006;
13(2):
541 - 558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma
Blood,
November 15, 2005;
106(10):
3538 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishida, S. Iida, Y. Akatsuka, T. Ishii, M. Miyazaki, H. Komatsu, H. Inagaki, N. Okada, T. Fujita, K. Shitara, et al.
The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma
Clin. Cancer Res.,
November 15, 2004;
10(22):
7529 - 7539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al.
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
Blood,
October 15, 2004;
104(8):
2484 - 2491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Niwa, S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yokoi, K. Nakamura, and K. Shitara
Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of Fc{gamma}RIIIa Functional Polymorphism
Clin. Cancer Res.,
September 15, 2004;
10(18):
6248 - 6255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Walter-Yohrling, X. Cao, M. Callahan, W. Weber, S. Morgenbesser, S. L. Madden, C. Wang, and B. A. Teicher
Identification of Genes Expressed in Malignant Cells That Promote Invasion
Cancer Res.,
December 15, 2003;
63(24):
8939 - 8947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiriva-Internati, Y. Liu, J. A. Weidanz, F. Grizzi, H. You, W. Zhou, K. Bumm, B. Barlogie, J. L. Mehta, and P. L. Hermonat
Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24
Blood,
November 1, 2003;
102(9):
3100 - 3107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Hashimoto, S. Ozaki, S. Wakatsuki, M. Kosaka, S. Kido, D. Inoue, et al.
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma
Blood,
August 28, 2002;
100(6):
2195 - 2202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
